Sensei Biotherapeutics, Inc. (SNSE)
| Market Cap | 357.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 18.90M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 21 |
| Last Price | $11.64 |
| Previous Close | $11.70 |
| Change ($) | -0.07 |
| Change (%) | -0.56% |
| Day's Open | 11.93 |
| Day's Range | 11.53 - 12.19 |
| Day's Volume | 37,010 |
| 52-Week Range | 9.05 - 26.50 |
According to the Double Buys page, a Premium feature of GuruFocus, five stocks that had multiple guru and insider buys during the second quarter are PennyMac Financial Services inc. ( PFSI , Financial),...
– Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated –
- ImmunoPhage™ platform programs and the VISTA program continue to advance -
BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generati...
Entrepreneurial leader brings expertise growing biotech platform companies Entrepreneurial leader brings expertise growing biotech platform companies
-Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds –
BOSTON and ROCKVILLE, Md., March 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutic...
BOSTON and ROCKVILLE, Md., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics...
BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics...
BOSTON & ROCKVILLE, Md.--Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced...
Sensei Biotherapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
Sensei Biotherapeutics, a Phase 2 biotech developing bacteriophage-based therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Sensei Biotherapeutics, a clinical-stage cancer immunotherapy company that opened a Boston research and development hub last year, has attracted high-profile investors for its $30 million Series B round.
About SNSE
Sensei Biotherapeutics is a clinical-stage immunotherapy company engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Monoclonal antibodies targeting the programmed cell death protein 1, or PD-1, and its related ligand, or PD-L1, have emerged as one of the most promising classes of therapeutics for the treatment of cancer. However, in a majority of patients they generally fail to produce meaningful results. Drugs utilizing PD-1 blockade have been approved by the FDA to treat at le... [Read more...]
| Industry Biotechnology | IPO Date Feb 4, 2021 |
| CEO John Celebi | Employees 30 |
| Stock Exchange NASDAQ | Ticker Symbol SNSE |